• Molecular NameQuazepam
  • SynonymQuazepamum [inn-latin]
  • Weight386.8
  • Drugbank_IDDB01589
  • ACS_NO36735-22-5
  • Show 3D model
  • LogP (experiment)4.03
  • LogP (predicted, AB/LogP v2.0)4.53
  • pkaN/A
  • LogD (pH=7, predicted)4.53
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-5.75
  • LogSw (predicted, AB/LogsW2.0)0.0
  • Sw (mg/ml) (predicted, ACD/Labs)0.0
  • No.of HBond Donors0
  • No.of HBond Acceptors2
  • No.of Rotatable Bonds3
  • TPSA47.69
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA drug which is a benzodiazepine derivative. Quazepam is indicated for the treatment of insomnia including sleep induction and sleep maintenance.
  • Absorption_valueN/A
  • Absorption (description)Quazepam is rapidly (absorption half-life of about 30 minutes) and well absorbed from the gastrointestinal tract.
  • Caco_2N/A
  • Bioavailability32.0
  • Protein binding95.0
  • Volume of distribution (VD)At bedtime, 5 L/kg and in the morning, 8.6 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmThe active metabolites of quazepam are 2-oxoquazepam and N-desalkyl-2-oxoquazepam. The N-desalkyl-2-oxoquazepam metabolite has only limited pharmacological activity compared to the parent compound quazepam and the active metabolite 2-oxoquazepam. Quazepam and its major active metabolite 2-oxoquazepam both show high selectivity for the type1 GABAA receptors.
  • Half life39 h
  • ExcretionIt is eliminated both renally and through feces.
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityAdverse events most frequently encountered in patients treated with quazepam are daytime drowsiness (12%) and headache (4.5%). Fatigue, dizziness, dry mouth, dyspepsia have been reported with frequency more than 1%.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A